EUVIMEDEUVIMED entdecken
Open Access

Diagnostic Value of CCL2 and CCR2 in Pleural Effusion for Distinguishing Lung Cancer Histological Subtypes: A Retrospective Study

Jie Yu iD, Yong Huang iD, Weirong Chen iD

Diagnostic Cytopathology · 2026

DOI: 10.1002/dc.70165 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diagnostic Cytopathology, 2026. Verfasst von Jie Yu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Nantong Haimen People's Hospital, Nantong, Jiangsu, China. Hauptthemen laut MEDLINE: Receptors, CCR2, Chemokine CCL2, Lung Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study evaluated the diagnostic value of C‐C motif chemokine ligand 2 (CCL2) and C‐C chemokine receptor type 2 (CCR2) in pleural effusions for distinguishing histological subtypes of lung cancer (LC).

Methods

A retrospective cohort study was conducted on 96 cases of squamous cell carcinoma (LUSC), 206 cases of lung adenocarcinoma (LUAD), and 53 cases of small cell LC (SCLC). A control group of 102 patients with parapneumonic effusion was selected. CCL2 and CCR2 levels in pleural effusions were measured. Pearson correlation analysis and receiver operating characteristic curve analysis were conducted.

Results

Pleural effusion CCL2 and CCR2 levels were higher in advanced LC than in parapneumonic effusion, and the changes in these two levels showed a moderate positive correlation ( p < 0.001). CCL2 and CCR2 levels in pleural effusions were elevated in LUAD patients compared to LUSC and SCLC patients ( p < 0.01), with SCLC patients having higher levels than LUSC patients ( p < 0.01). The AUC for the combined CCL2 and CCR2 panel was higher than that for CCL2, CCR2, carcinoembryonic antigen, and cytokeratin fragment antigen 21‐1 tested individually (all p < 0.05).

Conclusion

Patients with advanced LC exhibit elevated CCL2 and CCR2 levels in pleural effusions. Combined detection of these two markers has some diagnostic value in distinguishing between LUAD and LUSC, serving as a valuable supplement to histopathological examination; however, clinical application should involve a comprehensive assessment in conjunction with other auxiliary tests. These markers have limited value in distinguishing between SCLC and NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, CCR2Chemokine CCL2Lung NeoplasmsBiomarkers, TumorPleural Effusion, MalignantCarcinoma, Squamous CellSmall Cell Lung CarcinomaHumansFemaleRetrospective StudiesMaleMiddle AgedAgedDiagnosis, DifferentialAdult

Stichwörter der Autor:innen

CCL2CCR2differential diagnosishistological typelung cancerpleural effusions

Substanzen

Receptors, CCR2Chemokine CCL2CCR2 protein, humanCCL2 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Nantong Haimen People's Hospital, Nantong, Jiangsu, China.

ORCID-Profile: Jie Yu, Yong Huang, Weirong Chen

Zitieren

APA

Yu, J., Huang, Y., & Chen, W. (2026). Diagnostic Value of CCL2 and CCR2 in Pleural Effusion for Distinguishing Lung Cancer Histological Subtypes: A Retrospective Study. Diagnostic Cytopathology. https://doi.org/10.1002/dc.70165

Vancouver

Yu J, Huang Y, Chen W. Diagnostic Value of CCL2 and CCR2 in Pleural Effusion for Distinguishing Lung Cancer Histological Subtypes: A Retrospective Study. Diagnostic Cytopathology. 2026. doi:10.1002/dc.70165

BibTeX
@article{Yu2026,
  author = {Yu, Jie and Huang, Yong and Chen, Weirong},
  title = {Diagnostic Value of CCL2 and CCR2 in Pleural Effusion for Distinguishing Lung Cancer Histological Subtypes: A Retrospective Study},
  journal = {Diagnostic Cytopathology},
  year = {2026},
  doi = {10.1002/dc.70165}
}
Kostenlos starten →